Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 8/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763205 | 1.00 | PLG (0.40) | PLGPLATLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL25345937 | 0.86 | BTK (0.31) | BTK | |
| SCHEMBL5548176 | 0.83 | NR1H2 (0.36) | — | |
| SCHEMBL5549776 | 0.80 | — | — | |
| SCHEMBL5335883 | 0.80 | — | — | |
| SCHEMBL7275858 | 0.77 | — | — | |
| SCHEMBL5777420 | 0.76 | EP300 (0.36) | ANPEP | |
| SCHEMBL7772120 | 0.76 | — | — | |
| SCHEMBL3229403 | 0.72 | PLG (0.34) | PLGPLATLMNAKMT2ATAS2R14 | |
| SCHEMBL5024028 | 0.71 | KMT2A (0.48) | PLGPLATLMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458683-B1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7015325-B2 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2006-03-21 | — | — | US | disclosed |
| US-7012077-B2 | Substituted cyclohexane derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-6960588-B1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2005-11-01 | — | — | US | disclosed |
| EP-1458683-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-1244643-B1 | TRYPTASE INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003053933-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| US-20030083344-A1 | Tryptase inhibitors | ALTANA PHARMA AG (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-1244643-A1 | TRYPTASE INHIBITORS | ALTANA Pharma AG (DE) | 2002-10-02 | — | — | EP | disclosed |
| EP-1216236-A1 | TRYPTASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| EP-0714299-B1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001046168-A1 | TRYPTASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001019809-A1 | TRYPTASE INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-22 | — | — | WO | disclosed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5166403-A | Liquid crystals | SHOWA DENKO K.K. (JP) | 1992-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186984-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | PLG 3602/4885PLAT 4131/4885LMNA 794/4885 |
| US-20030083344-A1 | Tryptase inhibitors | TPSAB1, TPSB2, TPSG1 | PLG 1077/4885PLAT 570/4885LMNA 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.